1. Reduction in gefitinib resistance mediated by Yi-Fei San-Jie pill in non-small cell lung cancer through regulation of tyrosine metabolism, cell cycle, and the MET/EGFR signaling pathway
   Cai-Zhi Yang et al, 2023, Journal of Ethnopharmacology CrossRef
2. Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis
   Xiao-Yan Liu et al, 2024, World Journal of Gastrointestinal Surgery CrossRef
3. Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
   Wanhong Xu et al, 2019, Neoplasia CrossRef
4. Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications
   Tiziana Tataranni et al, 2019, Oxidative Medicine and Cellular Longevity CrossRef
5. Genes associated with diagnosis and prognosis of Burkitt lymphoma
   Albert Doughan et al, 2022, IET Systems Biology CrossRef
6. EGFR‐rich extracellular vesicles derived from highly metastatic nasopharyngeal carcinoma cells accelerate tumour metastasis through PI3K/AKT pathway‐suppressed ROS
   Fei Li et al, 2020, Journal of Extracellular Vesicles CrossRef
7. Oestrogen receptor β5 and epidermal growth factor receptor synergistically promote lung cancer progression
   Yuquan Bai et al, 2018, Autoimmunity CrossRef
8. CT2-3, a novel magnolol analogue suppresses NSCLC cells through triggering cell cycle arrest and apoptosis
   Jian Chen et al, 2020, Bioorganic & Medicinal Chemistry CrossRef
9. Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor
   Yaoshuai Zhang et al, 2023, European Journal of Pharmacology CrossRef
10. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
    Alexandre F. Aissa et al, 2021, Nature Communications CrossRef
11. Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets
    Nan Wei et al, 2020, Frontiers in Oncology CrossRef
12. Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer
    Piyada Sitthideatphaiboon et al, 2022, Scientific Reports CrossRef